Does competition equal lower prices? MS drugs defied cost logic as challengers swarmed in

Once only a small group of competitors, the field for multiple sclerosis (MS) therapies has exploded in recent years: By 2016, the number of approved drugs had nearly tripled in just seven years. That’s speedy growth, but something else grew faster—those drugs’ list prices.